Sergliflozin etabonate
Sergliflozin Etabonate (pronunciation: ser-gli-flo-zin e-ta-bo-nate) is a pharmaceutical drug that belongs to the class of Sodium-glucose cotransporter 2 (SGLT2) inhibitors. It is primarily used in the treatment of Type 2 diabetes.
Etymology
The name "Sergliflozin Etabonate" is derived from its chemical structure. "Sergli" is a prefix used in chemistry to denote a specific structural feature, while "flozin" is a suffix commonly used for drugs in the SGLT2 inhibitor class. "Etabonate" refers to the ester form of the drug, which enhances its solubility and absorption in the body.
Pharmacology
Sergliflozin Etabonate works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose from the urine back into the bloodstream. By inhibiting this protein, Sergliflozin Etabonate causes excess glucose to be excreted in the urine, thereby lowering blood glucose levels.
Clinical Use
Sergliflozin Etabonate is used in the management of Type 2 diabetes, often in combination with other antidiabetic medications. It may also be used in the treatment of Chronic kidney disease in patients with Type 2 diabetes, as it can help to protect the kidneys from damage caused by high blood glucose levels.
Side Effects
Common side effects of Sergliflozin Etabonate include urinary tract infections, increased urination, and genital yeast infections. Less common but more serious side effects can include dehydration, kidney problems, and diabetic ketoacidosis.
Related Terms
External links
- Medical encyclopedia article on Sergliflozin etabonate
- Wikipedia's article - Sergliflozin etabonate
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski